Suppr超能文献

原发性硬化性胆管炎的磁共振成像与超声早期胆管癌检测。

Early Cholangiocarcinoma Detection With Magnetic Resonance Imaging Versus Ultrasound in Primary Sclerosing Cholangitis.

机构信息

Division of Gastroenterology & Hepatology, Mayo Clinic, Rochester, MN.

Department of Radiology, Mayo Clinic, Rochester, MN.

出版信息

Hepatology. 2021 May;73(5):1868-1881. doi: 10.1002/hep.31575. Epub 2021 Apr 19.

Abstract

BACKGROUND AND AIMS

Early detection of perihilar cholangiocarcinoma (CCA) among patients with primary sclerosing cholangitis (PSC) is important to identify more people eligible for curative therapy. While many recommend CCA screening, there are divergent opinions and limited data regarding the use of ultrasound or magnetic resonance imaging (MRI) for early CCA detection, and it is unknown whether there is benefit in testing asymptomatic individuals. Our aims were to assess the diagnostic performances and prognostic implications of ultrasound and MRI-based CCA detection.

APPROACH AND RESULTS

This is a multicenter review of 266 adults with PSC (CCA, n = 120) who underwent both an ultrasound and MRI within 3 months. Images were re-examined by radiologists who were blinded to the clinical information. Respectively, MRI had a higher area under the curve compared with ultrasound for CCA detection: 0.87 versus 0.70 for the entire cohort; 0.81 versus 0.59 for asymptomatic individuals; and 0.88 versus 0.71 for those listed for CCA transplant protocol. The absence of symptoms at CCA diagnosis was associated with improved 5-year outcomes including overall survival (82% vs. 46%, log-rank P < 0.01) and recurrence-free survival following liver transplant (89% vs. 65%, log-rank P = 0.04). Among those with asymptomatic CCA, MRI detection (compared with ultrasound) was associated with reduction in both mortality (hazard ratio, 0.10; 95% confidence interval, 0.01-0.96) and CCA progression after transplant listing (hazard ratio, 0.10; 95% confidence interval, 0.01-0.90). These benefits continued among patients who had annual monitoring and PSC for more than 1 year before CCA was diagnosed.

CONCLUSIONS

MRI is superior to ultrasound for the detection of early-stage CCA in patients with PSC. Identification of CCA before the onset of symptoms with MRI is associated with improved outcomes.

摘要

背景和目的

在原发性硬化性胆管炎 (PSC) 患者中早期发现肝门部胆管癌 (CCA) 对于确定更多适合根治性治疗的患者非常重要。尽管许多人建议进行 CCA 筛查,但对于早期 CCA 检测中使用超声或磁共振成像 (MRI) 存在不同意见和有限的数据,并且尚不清楚在无症状个体中进行检测是否有益。我们的目的是评估基于超声和 MRI 的 CCA 检测的诊断性能和预后意义。

方法和结果

这是一项多中心回顾性研究,纳入了 266 名 PSC 成人患者(CCA 患者 n=120),他们在 3 个月内同时接受了超声和 MRI 检查。放射科医生在不知道临床信息的情况下重新检查了图像。对于整个队列,MRI 对 CCA 检测的曲线下面积 (AUC) 高于超声:0.87 比 0.70;对于无症状个体,AUC 分别为 0.81 比 0.59;对于列入 CCA 移植协议的个体,AUC 分别为 0.88 比 0.71。CCA 诊断时无症状与改善的 5 年结局相关,包括总生存率(82%比 46%,对数秩 P<0.01)和肝移植后无复发生存率(89%比 65%,对数秩 P=0.04)。在无症状 CCA 患者中,与超声相比,MRI 检测(与超声相比)与死亡率降低相关(风险比,0.10;95%置信区间,0.01-0.96)和移植名单后 CCA 进展减少(风险比,0.10;95%置信区间,0.01-0.90)。这些益处在 CCA 诊断前 PSC 监测和随访超过 1 年的患者中仍然存在。

结论

在 PSC 患者中,MRI 优于超声用于检测早期 CCA。MRI 在症状出现前识别 CCA 与改善结局相关。

相似文献

1
2
Cholangiocarcinoma and its mimickers in primary sclerosing cholangitis.
Abdom Radiol (NY). 2017 Dec;42(12):2898-2908. doi: 10.1007/s00261-017-1328-8.
5
Cholangiocarcinoma in Patients with Primary Sclerosing Cholangitis (PSC): a Comprehensive Review.
Clin Rev Allergy Immunol. 2020 Feb;58(1):134-149. doi: 10.1007/s12016-019-08764-7.
6
Prospective surveillance for cholangiocarcinoma in unselected individuals with primary sclerosing cholangitis.
J Hepatol. 2023 Mar;78(3):604-613. doi: 10.1016/j.jhep.2022.11.011. Epub 2022 Nov 19.
8
Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma.
J Hepatol. 2023 Jul;79(1):93-108. doi: 10.1016/j.jhep.2023.02.027. Epub 2023 Mar 1.
10
Volatile organic compounds in bile for early diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis: a pilot study.
Gastrointest Endosc. 2015 Apr;81(4):943-9.e1. doi: 10.1016/j.gie.2014.09.041. Epub 2014 Dec 12.

引用本文的文献

3
Artificial Intelligence and Radiomics in Cholangiocarcinoma: A Comprehensive Review.
Diagnostics (Basel). 2025 Jan 10;15(2):148. doi: 10.3390/diagnostics15020148.
4
Benign biliary conditions with increased risk of malignant lesions.
Abdom Radiol (NY). 2025 May;50(5):2038-2052. doi: 10.1007/s00261-024-04630-z. Epub 2024 Oct 22.
5
Comparative Performance of Quantitative and Qualitative Magnetic Resonance Imaging Metrics in Primary Sclerosing Cholangitis.
Gastro Hep Adv. 2022 Mar 30;1(3):287-295. doi: 10.1016/j.gastha.2022.01.003. eCollection 2022.
6
Surveillance MRI is associated with improved survival in patients with primary sclerosing cholangitis.
Hepatol Commun. 2024 May 2;8(5). doi: 10.1097/HC9.0000000000000442. eCollection 2024 May 1.
7
Application of AI on cholangiocarcinoma.
Front Oncol. 2024 Jan 29;14:1324222. doi: 10.3389/fonc.2024.1324222. eCollection 2024.
9
Advances in the Early Detection of Hepatobiliary Cancers.
Cancers (Basel). 2023 Jul 30;15(15):3880. doi: 10.3390/cancers15153880.
10
Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma.
J Hepatol. 2023 Jul;79(1):93-108. doi: 10.1016/j.jhep.2023.02.027. Epub 2023 Mar 1.

本文引用的文献

1
AGA Clinical Practice Update on Surveillance for Hepatobiliary Cancers in Patients With Primary Sclerosing Cholangitis: Expert Review.
Clin Gastroenterol Hepatol. 2019 Nov;17(12):2416-2422. doi: 10.1016/j.cgh.2019.07.011. Epub 2019 Jul 12.
2
Cancer risk, screening and surveillance in primary sclerosing cholangitis.
Minerva Gastroenterol Dietol. 2019 Sep;65(3):214-228. doi: 10.23736/S1121-421X.19.02586-8. Epub 2019 Jun 19.
3
Magnetic Resonance Imaging in Primary Sclerosing Cholangitis-Current State and Future Directions.
Semin Liver Dis. 2019 Jul;39(3):369-380. doi: 10.1055/s-0039-1687853. Epub 2019 Apr 30.
4
Emerging Technologies for the Diagnosis of Perihilar Cholangiocarcinoma.
Semin Liver Dis. 2018 May;38(2):160-169. doi: 10.1055/s-0038-1655775. Epub 2018 Jun 5.
5
Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis.
Gastroenterology. 2018 May;154(6):1706-1718.e1. doi: 10.1053/j.gastro.2018.01.064. Epub 2018 Feb 6.
6
Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis.
Hepatology. 2018 Jun;67(6):2338-2351. doi: 10.1002/hep.29730. Epub 2018 Apr 19.
7
CA 19-9 as a Marker of Survival and a Predictor of Metastization in Cholangiocarcinoma.
GE Port J Gastroenterol. 2017 May;24(3):114-121. doi: 10.1159/000452691. Epub 2017 Feb 23.
9
Primary Sclerosing Cholangitis as a Premalignant Biliary Tract Disease: Surveillance and Management.
Clin Gastroenterol Hepatol. 2015 Nov;13(12):2152-65. doi: 10.1016/j.cgh.2015.05.035. Epub 2015 Jun 5.
10
Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management.
Gastroenterology. 2013 Sep;145(3):521-36. doi: 10.1053/j.gastro.2013.06.052. Epub 2013 Jul 1.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验